ZVRA

Zevra Therapeutics Inc

Add to Watchlist

Advanced Chart

12.020

-0.11(-0.907%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

12.220

Open

12.104

VWAP

11.95

Vol

986.72K

Mkt Cap

657.25M

Low

11.575

Amount

11.79M

EV/EBITDA(TTM)

Total Shares

41.85M

660.72M

EV/OCF(TTM)

P/S(TTM)

14.74

Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

22.49M

+405.58%

24.32M

+558.11%

26.23M

+117.81%

Estimates Revision

The market is revising Downward the revenue expectations for Zevra Therapeutics, Inc. (ZVRA) for FY2025, with the revenue forecasts being adjusted by -6.27% over the past three months. During the same period, the stock price has changed by 52.73%.

Revenue Estimates for FY2025

Revise Downward

-6.27%

In Past 3 Month

Stock Price

Go Up

+52.73%

In Past 3 Month

7 Analyst Rating

101.08% Upside

Wall Street analysts forecast ZVRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZVRA is 24.17 USD with a low forecast of 19.00 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

101.08% Upside

Current: 12.020

Low

19.00

Averages

24.17

High

29.00

101.08% Upside

Current: 12.020

Low

19.00

Averages

24.17

High

29.00

Cantor Fitzgerald

NULL -> Overweight

maintain

$25 -> $29

2025-07-10

Reason

Cantor Fitzgerald

Price Target

$25 -> $29

2025-07-10

maintain

NULL -> Overweight

Reason

Cantor Fitzgerald raised the firm's price target on Zevra Therapeutics to $29 from $25 and keeps an Overweight rating on the shares. Miplyffa stands a good chance of approval in the EU, the analyst tells investors in a research note.

H.C. Wainwright

initiated

$26

2025-07-02

Reason

H.C. Wainwright

Price Target

$26

2025-07-02

initiated

Reason

H.C. Wainwright initiated coverage of Zevra Therapeutics with a Buy rating and $26 price target. Zevra has successfully launched Miplyffa for Niemann-Pick disease type C in the U.S. and the firm sees \"multiple levers for further long term value creation,\" the analyst tells investors. Even with the success of Miplyffa in the U.S., the firm believes the stock \"remains undervalued on the Miplyffa U.S. opportunity alone,\" the analyst added.

Citizens JMP

Jason Butler

Outperform

maintain

$18 -> $19

2025-05-14

Reason

Citizens JMP

Jason Butler

Price Target

$18 -> $19

2025-05-14

maintain

Outperform

Reason

Citizens JMP analyst Jason Butler raised the firm's price target on Zevra Therapeutics to $19 from $18 and keeps an Outperform rating on the shares. Zevra reported Q1 results and said the MIPLYFFA launch continues to exceed expectations, with 122 patient enrollment forms received, up from 109 at the end of December, the analyst tells investors in a research note. It is "highly encouraging" that new patient enrollment forms continue to increase beyond the cohort of patients in the U.S. extended access program, the firm says.

HC Wainwright & Co.

Oren Livnat

Strong Buy

Reiterates

$20

2025-03-13

Reason

HC Wainwright & Co.

Oren Livnat

Price Target

$20

2025-03-13

Reiterates

Strong Buy

Reason

Guggenheim

Eddie Hickman

Strong Buy

Maintains

$20 → $22

2025-03-13

Reason

Guggenheim

Eddie Hickman

Price Target

$20 → $22

2025-03-13

Maintains

Strong Buy

Reason

Guggenheim raised the firm's price target on Zevra Therapeutics to $22 from $20 and keeps a Buy rating on the shares. The Miplyffa launch is off to "a fast start" with U.S. sales of $10.1M for the first roughly one month of the launch, exceeding the firm's early expectations, the analyst tells investors.

Canaccord Genuity

Sumant Kulkarni

Strong Buy

Maintains

$23 → $25

2025-03-13

Reason

Canaccord Genuity

Sumant Kulkarni

Price Target

$23 → $25

2025-03-13

Maintains

Strong Buy

Reason

Canaccord analyst Sumant Kulkarni raised the firm's price target on Zevra Therapeutics to $25 from $23 and keeps a Buy rating on the shares. The firm said they reported its 4Q24 results showing sales of Miplyffa (arimoclomol) for Niemann-Pick Type C (NPC) came in at $10.1M versus estimates of $6.4M. Importantly, launch trends for the product remain encouraging, with the company receiving 109 total prescription forms versus 90 as of the last report.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Zevra Therapeutics Inc (ZVRA.O) is 7.77, compared to its 5-year average forward P/E of -6.59. For a more detailed relative valuation and DCF analysis to assess Zevra Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.59

Current PE

7.77

Overvalued PE

28.98

Undervalued PE

-42.16

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.00

Current EV/EBITDA

-109.51

Overvalued EV/EBITDA

24.21

Undervalued EV/EBITDA

-32.22

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

9.40

Current PS

5.75

Overvalued PS

16.96

Undervalued PS

1.84

Financials

Annual

Quarterly

FY2025Q1

YoY :

+495.65%

20.40M

Total Revenue

FY2025Q1

YoY :

-73.83%

-5.36M

Operating Profit

FY2025Q1

YoY :

-81.36%

-3.10M

Net Income after Tax

FY2025Q1

YoY :

-85.00%

-0.06

EPS - Diluted

FY2025Q1

YoY :

-48.52%

-8.32M

Free Cash Flow

FY2025Q1

YoY :

+70.03%

85.49

Gross Profit Margin - %

FY2025Q1

YoY :

+0.83%

-167.10

FCF Margin - %

FY2025Q1

YoY :

-96.87%

-15.19

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

221.0K

USD

3-6

Months

0.0

USD

6-9

Months

920.0K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

82.0K

USD

Months

6-9

0.0

USD

Months

0-12

4.0K

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

601.6K

Volume

Months

6-9

596.1K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

221.0K

USD

3-6

Months

0.0

USD

6-9

Months

920.0K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

82.0K

USD

Months

6-9

0.0

USD

Months

0-12

4.0K

USD

Months

ZVRA News & Events

Events Timeline

2025-07-28 (ET)

2025-07-28

06:04:38

Zevra Therapeutics submits MAA to EMA for evaluation of arimoclomol

2025-07-18 (ET)

2025-07-18

07:33:15

Zevra Therapeutics announces MIPLYFFA , OLPRUVA presentations at SERGG

2025-07-16 (ET)

2025-07-16

07:33:40

Zevra Therapeutics announces publication of results on Phase 2/3 NPC-002

News

3.0

08-04Newsfilter

Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call

9.0

07-28Newsfilter

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

9.0

07-16Newsfilter

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism